Brain’s ‘Override Switch’ for Chronic Pain Discovered, Offering New Treatment Pathways
A groundbreaking study published in Nature reveals a potential “override switch” in the brain that could offer new avenues for treating chronic pain, a condition affecting roughly 50 million adults in the United States. Researchers have identified a specific group of neurons that appear to dampen pain signals when more urgent survival needs – like hunger,fear,or thirst – take precedence.
Chronic pain differs drastically from acute pain, which serves as a vital warning system. While short bursts of pain alert us to immediate harm – touching a hot surface, such as – chronic pain persists long after an injury has healed. “It’s not just an injury that won’t heal,” explains a neuroscientist at the University of Pennsylvania, J. Nicholas betley, “it’s a brain input that’s become sensitized and hyperactive, and determining how to quiet that input could lead to better treatments.”
The research team, led by Betley and collaborators from the University of Pittsburgh and Scripps Research Institute, focused on a group of brainstem cells called Y1 receptor (Y1R)-expressing neurons, located in the lateral parabrachial nucleus (lPBN). These neurons are activated during persistent pain states, but also process signals related to fundamental drives like hunger, fear, and thirst. This suggests the brain possesses a mechanism to modulate pain based on immediate needs. The team discovered that the nucleus can filter sensory input to quiet pain when immediate survival is paramount. “That told us the brain must have a built-in way of prioritizing urgent survival needs over pain, and we wanted to find the neurons responsible for that switch,” Goldstein stated.
The Role of Neuropeptide Y
A key component of this “switch” is neuropeptide Y (NPY), a signaling molecule that helps the brain balance competing needs. When hunger or fear takes precedence, NPY acts on Y1 receptors in the parabrachial nucleus to dampen ongoing pain signals.”It’s like the brain has this built-in override switch,” Goldstein explains. “If you’re starving or facing a predator, you can’t afford to be overwhelmed by lingering pain. Neurons activated by these othre threats release NPY, and NPY quiets the pain signal so that other survival needs take precedence.”
Interestingly, the researchers found that Y1R neurons aren’t neatly organized. Rather of forming distinct anatomical or molecular populations, they are “scattered across many other cell types.” Betley described this distribution as “like looking at cars in a parking lot…the Y1R neurons are like yellow paint distributed across red cars, blue cars, and green cars.” This mosaic distribution may allow the brain to dampen various types of painful inputs across multiple circuits. .
Future Directions in Pain treatment
Betley is enthusiastic about the potential to “use Y1 neural activity as a biomarker for chronic pain, something drug developers and clinicians have long lacked.” Currently, patients frequently enough seek help from specialists without a clear indication of the underlying cause of their pain. “What we’re showing is that the problem may not be in the nerves at the site of injury, but in the brain circuit itself,” Betley notes. “If we can target these neurons, that opens up a whole new path for treatment.”
The research also suggests that behavioral interventions – such as exercise, meditation, and cognitive behavioral therapy – could influence these brain circuits, mirroring the effects of hunger and fear observed in the lab. “We’ve shown that this circuit is flexible, it can be dialed up or down,” Betley says. “So, the future isn’t just about designing a pill. It’s also about asking how behavior, training, and lifestyle can change the way these neurons encode pain.”
The study involved contributions from researchers at the University of Pennsylvania, University of Pittsburgh, Scripps Research Institute, Carleton University, University of Florida College of Medicine, and other institutions, and was supported by a range of grants and fellowships from organizations including the Klingenstein Foundation, the National Institutes of Health, and the National Science Foundation.
